C.E.M. Griffiths
Impact in
- Dermatology top 0.01%
- Dermatology and Skin Diseases
- Skin Protection and Aging
- Immunology top 0.01%
- Psoriasis: Treatment and Pathogenesis
Papers in
- Immunology 413
- Psoriasis: Treatment and Pathogenesis 362
- T-cell and B-cell Immunology 25
- Dermatology 240
- Dermatology and Skin Diseases 124
- Skin Protection and Aging 85
- Co-authors
- Darren M. Ashcroft (61 shared papers)Rosa Parisi (19 shared papers)Helen L. Richards (34 shared papers)Dónal G. Fortune (25 shared papers)John J. Voorhees (37 shared papers)Deborah Symmons (6 shared papers)Kim Papp (34 shared papers)Chris J. Main (21 shared papers)
- Journals
- British Journal of Dermatology (215 papers)Journal of Investigative Dermatology (63 papers)Clinical and Experimental Dermatology (43 papers)Journal of the American Academy of Dermatology (39 papers)Journal of the European Academy of Dermatology and Venereology (29 papers)
- Partner nations
- United KingdomUnited StatesGermany
In The Last Decade
C.E.M. Griffiths
726 papers receiving 45.1k citations
C.E.M. Griffiths's Hit Papers
Peers
Comparison fields: 5 of 205
- Dermatology 15.9k
- Immunology 25.6k
- Immunology and Allergy 1.9k
- Rheumatology 4.6k
- Complementary and Manual Therapy 532
Countries citing papers authored by C.E.M. Griffiths
This map shows the geographic impact of C.E.M. Griffiths's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.E.M. Griffiths with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.E.M. Griffiths more than expected).
Fields of papers citing papers by C.E.M. Griffiths
This network shows the impact of papers produced by C.E.M. Griffiths. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.E.M. Griffiths. The network helps show where C.E.M. Griffiths may publish in the future.
Co-authors
The 25 scholars most cited alongside C.E.M. Griffiths, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 757 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence Hit paper breakdown → | 2012 | 1991 |
| 2 | Pathogenesis and clinical features of psoriasis Hit paper breakdown → | 2007 | 1674 |
| 3 | Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Hit paper breakdown → | 2014 | 1547 |
| 4 | Psoriasis Hit paper breakdown → | 2021 | 1475 |
| 5 | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Hit paper breakdown → | 2005 | 859 |
| 6 | National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study Hit paper breakdown → | 2020 | 786 |
| 7 | Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Hit paper breakdown → | 2015 | 673 |
| 8 | Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis Hit paper breakdown → | 2010 | 670 |
| 9 | Keratinocytes as initiators of inflammation Hit paper breakdown → | 1991 | 666 |
| 10 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Hit paper breakdown → | 2017 | 658 |
| 11 | A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Hit paper breakdown → | 2005 | 573 |
| 12 | Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Hit paper breakdown → | 2015 | 504 |
| 13 | 1989 | 468 | |
| 14 | Cellular localization of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriasis. | 1991 | 397 |
| 15 | Restoration of Collagen Formation in Photodamaged Human Skin by Tretinoin (Retinoic Acid) Hit paper breakdown → | 1993 | 387 |
| 16 | 1995 | 335 | |
| 17 | 2013 | 328 | |
| 18 | 2009 | 326 | |
| 19 | 2019 | 315 | |
| 20 | Psoriasis Prevalence in Adults in the United States Hit paper breakdown → | 2021 | 298 |
About C.E.M. Griffiths
C.E.M. Griffiths is a scholar working on Immunology, Dermatology, Molecular Biology, Pathology and Forensic Medicine and Cell Biology, having authored 757 papers that have together received 47.2k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (362 papers), Dermatology and Skin Diseases (124 papers), Skin Protection and Aging (85 papers), Autoimmune Bullous Skin Diseases (48 papers), Retinoids in leukemia and cellular processes (34 papers), Asthma and respiratory diseases (32 papers), melanin and skin pigmentation (27 papers) and T-cell and B-cell Immunology (25 papers). The work is most often cited by research in Dermatology (15.9k citations), Immunology (25.6k citations), Immunology and Allergy (1.9k citations), Rheumatology (4.6k citations) and Complementary and Manual Therapy (532 citations). C.E.M. Griffiths has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Darren M. Ashcroft, Rosa Parisi, Helen L. Richards, Dónal G. Fortune, John J. Voorhees, Deborah Symmons, Kim Papp, Chris J. Main, Rachel Watson and Kristian Reich. Their work appears in journals such as British Journal of Dermatology, Journal of Investigative Dermatology, Clinical and Experimental Dermatology, Journal of the American Academy of Dermatology and Journal of the European Academy of Dermatology and Venereology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.